Evidence map›Paper›PMID 28414916›Full record

ArticleACS nano2017

Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles.

Kaili Hu, Lei Miao, Tyler J Goodwin, Jun Li, Qi Liu, Leaf Huang

Open access · greenAbstract read
In one paragraph

Article in ACS nano, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 1 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 1 synthesis or guideline pooled it, 282 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Dual-modality immune nano-activator harnessing MnJournal of nanobiotechnology · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Kaili HuDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Lei MiaoDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Tyler J GoodwinDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Jun LiDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Qi LiuDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Leaf HuangDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-9421-8283
University of North Carolina at Chapel Hill · US

Funding

Translational Nanosystems for Improved Lung Cancer Treatment with Small MoleculesU54CA151652 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAROON, ZISHAN A, TEPPER, JOEL E · 2010 to 2014
$12.1M
Small Animal Imaging CoreU54CA198999 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO · 2015 to 2019
$11.9M
Hepatic Non-viral Gene TherapyR01DK100664 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUANG, LEAF · 2013 to 2017
$1.7M
Nanocrystals for the Treatment of Multidrug Resistance in CancerR01CA149387 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUANG, LEAF · 2011 to 2015
$1.5M
Novel nanoparticles for siRNA deliveryR01CA149363 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUANG, LEAF · 2010 to 2014
$1.3M
NCI NIH HHS R01 CA149363NCI NIH HHS R01 CA149387NCI NIH HHS U54 CA151652NCI NIH HHS U54 CA198999NIDDK NIH HHS R01 DK100664
6 · The paper itself

Abstract

Our previous work demonstrated that Wnt16 expression in cisplatin-damaged tumor-associated fibroblasts is a key factor contributing to cisplatin resistance in malignancies. Natural antifibrotic compounds with low toxicities are promising candidates to downregulate Wnt16 expression, improving the antitumor effect of cisplatin nanoparticles. Upon screening several natural chemicals, we found that a dietary flavonoid, quercetin, significantly suppresses Wnt16 expression in activated fibroblasts. To facilitate drug delivery, we have prepared a targeted lipid/calcium/phosphate nanoparticle formulation consisting of a prodrug of quercetin, i.e., quercetin phosphate, with a high loading efficiency (26.6% w/w). This quercetin nanoparticle with a particle size of around 35 nm significantly improved the bioavailability and metabolic stability of the parent quercetin. Quercetin phosphate is released from the nanoparticles and converted back to the parent quercetin under physiological conditions. Following systemic administration of quercetin phosphate nanoparticles, a significant downregulation in Wnt16 expression was observed and further yielded a synergistic antitumor effect with cisplatin nanoparticles in a stroma-rich bladder carcinoma model. The α-SMA-positive fibroblast and collagen within the tumor decreased significantly after combination treatment. This suggests that the remodeling of the tumor microenvironment induced by quercetin plays a critical role in promoting the synergy. Indeed, our data further confirmed that quercetin phosphate alone significantly remodeled the tumor microenvironment and increased the penetration of second-wave nanoparticles into the tumor nests. Collectively, quercetin phosphate nanoparticles may be a safe and effective way to improve therapeutic treatment for desmoplastic tumors.

Indexed as

AnimalsApoptosisBiological AvailabilityCell Line, TumorCisplatinDrug Delivery SystemsDrug Resistance, NeoplasmHumansLipidsMiceMice, NudeNanoparticlesNIH 3T3 CellsParticle SizeQuercetinTumor MicroenvironmentCisplatinLipidsQuercetinWnt16 protein, mouseWnt Proteinscisplatinnanoparticlequercetintumor microenvironmentWnt16

Identifiers

PMID28414916
PMCPMC5961944
OpenAlexW2607351395

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.